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A B S T R A C T
A preliminary mass spectrometry based shotgun protocol was set up to compare the peptidome of
plasma samples from healthy and hemorrhagic shock rats with the aim of verifying the possible role of
uncontrolled proteolytic activity in circulatory shock. Since the hemorrhagic shock model requires
heparin as anticoagulant, a preliminary experiment using plasma sample obtained in the presence/
absence of heparin from healthy rats was performed to determine whether its presence is fully
compatible with the peptidomic protocol proposed. The entire protocol was tested in a pilot experiment
to compare the peptidome of healthy or heparin-anticoagulated rats subjected to hemorrhagic shock.
ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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journal homepa ge: www.elsev ier .com/locate /euprotCirculatory shock is a frequent cause of death and a most
important unresolved medical problem [1,2]. Several studies have
found that intestine failure triggers a diffuse inﬂammatory state
[3], which can contribute to the development of multiple organ
dysfunction (MODS) and post-HS death.
In hemorrhage and sepsis, the intestinal mucosal barrier may
become severely damaged due to hypoperfusion. As a consequence
many enteral digestive enzymes, such as proteases and lipases may
escape from the intestinal lumen and reach the systemic
circulation, resulting in global cellular and organ dysfunction [4].
To test the hypothesis that in hemorrhagic shock there is an
increase of proteases activity, we use for the ﬁrst time, a high-
throughput quantitative mass spectrometry-based approach to
analyze the peptidome of rat plasma collected after hemorrhagic
shock (HS) and plasma of healthy control rats (CTRL) in order to
quantify the relative changes. The experimental hemorrhagic
shock model (HS) requires the use of heparin as anticoagulant. Due
to the peculiar chemical properties of this highly acidic polymeric* Corresponding author.
E-mail address: elisa.mafﬁoli@guest.unimi.it (E. Mafﬁoli).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).compound, preliminary experiments need to be performed to
determine whether its presence is fully compatible with the
analytical approach proposed since, to the best of our knowledge,
shot-gun nanoLC-ESI–MS/MS has never been used to investigate
heparin-containing plasma peptidome.
1 mL venous blood sample was collected from healthy animals
in a vial after the addition of a protease inhibitor solution
(cOmpleteTM Protease Inhibitor Cocktail, Roche) with or without
1 unit heparin/mL (EDTA + heparin) or (EDTA), respectively. Due to
the high complexity and wide dynamic range of plasma peptides
and proteins, we applied a two-step enrichment method to
selectively extract peptides and low molecular weight compo-
nents, which are low abundant in plasma. 500 mL of each plasma
sample were diluted with an equal volume of 32% (v/v) acetic acid
to favor disruption of peptide/protein interactions and ultra-
ﬁltrated with a 10 kDa cut-off ﬁlter (Centricon 10, Millipore) to
deplete the high molecular weight proteins. The ﬁltrate was then
precipitated with two volumes of cold acetonitrile containing 0.1%
of triﬂuoroacetic acid to complete the removal of any residual high
molecular weight component. The supernatant from each sample
was then dried (Speed Vacuum), dissolved in 1% (v/v) formic acid,ics Association (EuPA). This is an open access article under the CC BY-NC-ND license
Table 1
Number of the peptides and proteins from which the peptides originate identiﬁed in
EDTA + Heparin and EDTA plasma samples with FDR 5% and FDR 1%, respectively.
EDTA + Heparin EDTA
FDR 5% FDR 1% FDR 5% FDR 1%
No. of peptides 184 138 153 104
No. of proteins 177 128 150 99
2 E. Mafﬁoli et al. / EuPA Open Proteomics 12 (2016) 1–3desalted (Zip-Tip C18, Millipore) and directly analyzed by nanoLC-
ESI MS/MS.
Mass spectrometry analysis was performed using a LTQ
Orbitrap Velos (Thermo Fisher Scientiﬁc) equipped with a Dionex
UltiMate 3000HPLC System as reported in [5]. Data acquisition was
controlled by Xcalibur 2.0 and Tune 2.4 software. Mass spectra
were analyzed using MaxQuant software (version 1.3.0.5). The
initial maximum allowed mass deviation was set to 15 ppm for
monoisotopic precursor ions and 0.5 Da for MS/MS peaks. Enzyme
speciﬁcity was set to unspeciﬁc, a maximum of two missed
cleavages were allowed, N-terminal acetylation, methionine
oxidation, and asparagine/glutamine deamidation were set as
variable modiﬁcations. The spectra were searched by the
Andromeda search engine in MaxQuant [6] against the rat Uniprot
sequence database (release 03.12.2014) setting required false
positive rate both to 5% or 1% at the peptide and protein level (in
order to detect potential effects of the content of the starting
sample on the ﬁnal identiﬁcation conﬁdence) and the minimum
required peptide length to 6 amino acids. The reversed sequences
of the target database were used as decoy database. Comparative
analyses were performed using the Perseus software (version
1.4.0.6, http://coxdocs.org/doku.php?id=perseus:start).
As shown in Table 1, 138 and 104 peptides were identiﬁed in
plasma with (EDTA + heparin) and without heparin (EDTA),
respectively, at 1% FDR; among them 37 peptides were present
in both conditions. Thus, the analysis allows detecting a similar
number of peptides, suggesting that heparin is indeed compatible
with the proposed protocol for plasma peptide enrichment and
identiﬁcation. In accordance, the fraction of peptides identiﬁed
with 1% or 5% FDR is similar for both samples, implying that the
presence of heparin does not alter the peptide identiﬁcationFig. 1. A) Venn diagram of the peptides identiﬁed in hemorrhagic (HS) and healthy (C
peptides originate in hemorrhagic (HS) and healthy (CTRL) rats with FDR 5%. C) Venn diag
1%. D) Venn diagram of the proteins from which the identiﬁed peptides originate in hconﬁdence obtained through the nanoLC-ESI–MS/MS analysis.
Finally, analysis of the C-terminal residue indicates that 58% or 67%
of the peptides identiﬁed in the absence or presence of heparin,
respectively, were potentially generated by chymotrypsin-like
enzymes, while 37% or 32% of the peptides identiﬁed in the
absence or presence of heparin, respectively, were potentially
generated by trypsin-like enzymes. In conclusion, the presence of
heparin does not hamper the detection of peptides originated from
any particular protease.
It was then veriﬁed whether the protocol is suited to analyze
real samples, i.e. plasma from heparin-anti-coagulated rats
subjected to hemorrhagic shock (HS), an essential step preliminary
to a more comprehensive analysis that will be carried out on a
larger number of control and shock animals.
Two male Wistar rats (300–450 g, Harlan Laboratories, Inc.,
Indianapolis, IN) were assigned to either a control (CTRL) or a
hemorrhagic shock (HS) group. Both HS and CTRL animals were
heparinized (porcine heparin) following an initial stabilization
after the induction of anesthesia (1 unit heparin/mL total blood
volume, estimated at 6% of the body weight). Hemorrhage was
induced by blood withdrawal from the femoral vein (0.5 mL/min)
to a target mean arterial pressure (MAP) of 35 mmHg. Hypovo-
lemia was maintained for two hours, at which point the shed blood
was reinfused (0.5 mL/min). Samples were then centrifuged at
1300 rpm for 10 min and the supernatant analyzed following the
protocol described above. The animal protocol was reviewed and
approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of California, San Diego and conforms to
the Guide for the Care and Use of Laboratory Animals by the United
States National Institutes of Health (NIH Publication No. 85–23,
1996).
The peptidome of plasma samples from healthy and hemor-
rhagic shock rats was compared to identify and quantify the
peptides present in plasma. Four technical replicate MS analyses
were performed for each sample, CTRL and HS. Supplementary
Material Fig. S1 compares the distribution of relevant parameters
(precursor charge and molecular mass and mass error) relative to
peptides identiﬁed in the analysis of CTRL and HS. The average
molecular mass of peptides identiﬁed in CTRL and HS was 1908 and
1913 Da, respectively.TRL) rats with FDR 5%. B) Venn diagram of the proteins from which the identiﬁed
ram of the peptides identiﬁed in hemorrhagic (HS) and healthy (CTRL) rats with FDR
emorrhagic (HS) and healthy (CTRL) rats with FDR 1%.
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were considered as positively identiﬁed and quantiﬁed. Peptides
were considered increased or decreased if they were present only
in either the healthy or hemorrhagic animal or if they showed 50%
fold change differences (>1.5-fold increase or <0.67-fold decrease)
in HS compared to CTRL, as calculated from the ratio of mean XIC-
based label free quantiﬁcation [7].
Fig. 1 A-D shows the number of peptides and proteins from
which peptides originate identiﬁed in CTRL and HS at 5% (A and B)
or 1% (C and D) FDR. Again, the fraction of peptides identiﬁed at 1%
compared to 5% FDR is similar for the two samples.
164 and 320 peptides were identiﬁed in the CTRL and HS,
respectively, at 5% FDR (Fig. 1A); among the 118 peptides present in
both CTRL and HS, 50 increased (>1.5 fold-change) and 52 de-
creased (<0.67 fold change) in concentration in HS. Overall, the
analysis identiﬁed 252 peptides, which were increased or present
only in HS while 98 peptides were decreased or present only in the
control clearly showing a signiﬁcantly increased number of
peptides possibly derived from an intrinsic proteolytic activity
in HS samples compared to CTRL. Comparison of the number of
peptides identiﬁed in two similar samples, i.e. healthy animals
(164, Fig. 1A) and plasma from healthy animals with added heparin
(184, EDTA + Heparin, Table 1), suggests that the overall protocol is
reproducible.
The analysis at the protein level identiﬁed 139 proteins which
underwent higher proteolysis (>1.5 fold-change, 36 proteins) or
proteolyzed only in hemorrhagic shock (HS, 113 proteins) while
46 proteins were less proteolysed in HS (<0.67 fold change,
21 proteins) or proteolyzed only in the control (CTRL, 25 proteins)
(Fig. 1B).
The main ﬁnding of this work is that heparin is an anticoagulant
agent compatible with the proposed peptidomic protocol. Our
preliminary data support and quantitately suggest an increase in
peptides possibly generated by digestive enzymes after hemor-
rhagic shock conﬁrming that proteolytic activity takes place after
HS in accordance with the “Autodigestion Hypothesis” [4].
Complete conﬁrmation of the above hypothesis, including a
statistically supported list of the speciﬁc peptides generated
during shock, however requires validation using a higher number
of animals.
This high-throughput mass spectrometry-based approach
appears ideal to expand our understanding of postshock patho-
physiology and to aid in the identiﬁcation of causative agents.Thanks to its simplicity, the experimental conditions of sample
treatment and analysis of plasma peptides set up in the present
communication will be helpful to extend our studies to different
animal models and different types of shock (i.e., cardiogenic shock,
septic shock etc.).
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